Type I IFN signalling in cDC1s promotes their accumulation at the tumor site, enhances their immunogenic maturation as well as their cross‐presentation ability68, 69 and improves type III IFN secretion70 together with the trans‐presentation of IL‐15, which promotes proliferation of CTLs.71 The gene discussed is IL15; the disease is neoplasm.